Lectenz® Bio receives patent issuance from USPTO

The Lectenz® Bio team is excited to announce the approval of its first patent for a carbohydrate-like small molecule inhibitor.

This expands the Lectenz® product pipeline with a small molecule glycomimetic which has therapeutic potential as a flu inhibitor. This paves the way for more research and development for both Lectenz® and GlycoSense products.

 

More about the patent: 

Glycomimetics to Inhibit Pathogen-Host Interactions. U.S. Patent Number 9,605,014. This patent is for carbohydrate-like small molecule inhibitors. (Patent issued by USPTO March 28, 2017.)